Literature DB >> 9797569

Parvovirus B19 infection, hepatitis C virus infection, and mixed cryoglobulinaemia.

P Cacoub1, N Boukli, P Hausfater, A Garbarg-Chenon, P Ghillani, V Thibault, L Musset, J M Huraux, J C Piette.   

Abstract

BACKGROUND: Infection with human parvovirus B19 (B19) has been reported in a few patients with various vasculitis syndromes. Mixed cryoglobulinaemia (MC), a model of small vessel size vasculitis, may result from numerous infectious diseases, particularly hepatitis C virus (HCV) infection. AIM: To assess the prevalence of seric B19 infection markers in a large series of patients with MC, with or without HCV infection. PATIENTS AND METHODS: Sixty-four patients were studied: essential MC (EMC, n = 19), MC associated with non-infectious diseases (non-essential MC, n = 9), and patients with HCV infection with (HCV-MC, n = 18) or without MC (HCV-no-MC, n = 18). Patients were considered to have MC if two successive determinations of their serum cryoglobulin concentration were above 0.05 g/l. Serum samples were analysed for specific IgG and IgM antibodies to B19 by enzyme immunoassay. B19 DNA detection was performed by polymerase chain reaction using a set of primers located in the VP1 gene, separately in serum and in cryoprecipitates to investigate a possible capture of B19 DNA in cryoprecipitate. The study also looked for a possible enrichment for of IgG antibodies to B19 in MC.
RESULTS: The presence of specific IgG antibodies to B19 was found in 68% EMC, 56% non-essential MC, 78% HCV-MC, and 78% HCV-no-MC. No patient of either group had specific IgM antibodies to B19, or B19 DNA in serum or in cryoprecipitate. Overall, IgG antibodies to B19 were found in 46 of 64 (72%) serum samples, a prevalence quite similar to the prevalence in general adult population (> 60%). A specific enrichment of IgG antibodies to B19 in the MC was not found.
CONCLUSION: These results suggest that B19 infection is neither an aetiological factor of EMC, nor a cofactor that may lead to MC production in patients with chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797569      PMCID: PMC1752657          DOI: 10.1136/ard.57.7.422

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  31 in total

1.  Polyarteritis nodosa and parvovirus B19 infection.

Authors:  L C Corman; D J Dolson
Journal:  Lancet       Date:  1992-02-22       Impact factor: 79.321

2.  Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia.

Authors:  C Ferri; F Greco; G Longombardo; P Palla; A Moretti; E Marzo; P V Fosella; G Pasero; S Bombardieri
Journal:  Arthritis Rheum       Date:  1991-12

3.  Characterization of cryoglobulins by immunoblotting.

Authors:  L Musset; M C Diemert; F Taibi; L Thi Huong Du; P Cacoub; J M Leger; G Boissy; O Gaillard; J Galli
Journal:  Clin Chem       Date:  1992-06       Impact factor: 8.327

Review 4.  Hematologic and hematopoietic consequences of B19 parvovirus infection.

Authors:  N Young
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

5.  Hepatitis C virus and cryoglobulinemia.

Authors:  P Cacoub; F Lunel; L Musset; P Opolon; J C Piette
Journal:  N Engl J Med       Date:  1993-04-15       Impact factor: 91.245

6.  Polyarteritis nodosa and parvovirus B19.

Authors:  M Leruez-Ville; A Laugé; F Morinet; L Guillevin; P Dény
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

7.  Parvovirus B19 and erosive polyarthritis.

Authors:  A Tyndall; W Jelk; H H Hirsch
Journal:  Lancet       Date:  1994-02-19       Impact factor: 79.321

8.  A role for hepatitis C virus infection in type II cryoglobulinemia.

Authors:  V Agnello; R T Chung; L M Kaplan
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

9.  Mixed cryoglobulinemia and hepatitis C virus.

Authors:  P Cacoub; F L Fabiani; L Musset; M Perrin; L Frangeul; J M Leger; J M Huraux; J C Piette; P Godeau
Journal:  Am J Med       Date:  1994-02       Impact factor: 4.965

10.  Immunological disorders in C virus chronic active hepatitis: a prospective case-control study.

Authors:  J M Pawlotsky; M Ben Yahia; C Andre; M C Voisin; L Intrator; F Roudot-Thoraval; L Deforges; C Duvoux; E S Zafrani; J Duval
Journal:  Hepatology       Date:  1994-04       Impact factor: 17.425

View more
  1 in total

Review 1.  Infection and vasculitis.

Authors:  Cristina C Belizna; Mohamed A Hamidou; Hervé Levesque; Loic Guillevin; Yehuda Shoenfeld
Journal:  Rheumatology (Oxford)       Date:  2009-03-03       Impact factor: 7.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.